Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus

被引：0
|
作者：
Da Mutten, Raffaele [1 ,2 ]
Cetrez, Nursen [1 ]
Lindblom, Julius [1 ]
Oon, Shereen [3 ]
Nikolopoulos, Dionysis [1 ,2 ]
Nikpour, Mandana [4 ,5 ]
Parodis, Ioannis [1 ,2 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Karolinska Univ Hosp, Div Rheumatol, Dept Med Solna, Stockholm, Sweden
[3] St Vincents Hosp, Fitzroy, Vic, Australia
[4] Univ Melbourne, St Vincents Hosp Melbourne, Dept Med, Melbourne, Vic, Australia
[5] Univ Melbourne, St Vincents Hosp Melbourne, Dept Rheumatol, Melbourne, Vic, Australia
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2320
引用
收藏
页码：4596 / 4597
页数：2
相关论文
共 50 条
  • [11] ATTAINMENT OF LOW DISEASE ACTIVITY AND REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH HIGH DISEASE ACTIVITY IN THE ATACICEPT PHASE IIB ADDRESS II STUDY AND ITS LONG-TERM EXTENSION
    Morand, E.
    Merrill, J. T.
    Isenberg, D. A.
    Kao, A. H.
    Vazquez-Mateo, C.
    Wax, S.
    Chang, P.
    Pudota, K.
    Aranow, C.
    Wallace, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 174 - 178
  • [12] PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Parodis, Ioannis
    Johansson, Petter
    Gomez, Alvaro
    Soukka, Sofia
    Emamikia, Sharzad
    Chatzidionysiou, Katerina
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 761 - 761
  • [13] Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus
    Tselios, Konstantinos
    Gladman, Dafna D.
    Touma, Zahi
    Su, Jiandong
    Anderson, Nicole
    Urowitz, Murray B.
    ARTHRITIS CARE & RESEARCH, 2019, 71 (06) : 822 - 828
  • [14] Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
    Parodis, Ioannis
    Johansson, Petter
    Gomez, Alvaro
    Soukka, Sofia
    Emamikia, Sharzad
    Chatzidionysiou, Katerina
    RHEUMATOLOGY, 2019, 58 (12) : 2170 - 2176
  • [15] Defining Low Disease Activity in Systemic Lupus Erythematosus
    Polachek, Ari
    Gladman, Dafna D.
    Su, Jiandong
    Urowitz, Murray
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [16] Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
    Morand, E. F.
    Abreu, G.
    Furie, R. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (05)
  • [17] Defining Low Disease Activity in Systemic Lupus Erythematosus
    Polachek, Ari
    Gladman, Dafna D.
    Su, Jiandong
    Urowitz, Murray B.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (07) : 997 - 1003
  • [18] Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
    Morand, Eric F.
    Abreu, Gabriel
    Furie, Richard A.
    Golder, Vera
    Tummala, Raj
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (05) : 639 - 645
  • [19] REMISSION AND LOW LUPUS DISEASE ACTIVITY (LLDAS) ARE ASSOCIATED WITH BETTER PATIENT-REPORTED OUTCOMES (PROS) IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    Ugarte-Gil, Manuel F.
    Gamboa-Cardenas, Rocio
    Reategui-Sokolova, Cristina
    Pimentel-Quiroz, Victor
    Medina, Mariela
    Elera-Fitzcarrald, Claudia
    Cucho-Venegas, Jorge M.
    Rodriguez-Bellido, Zoila
    Pastor-Asurza, Cesar
    Alarcon, Graciela S.
    Perich-Campos, Risto
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S17 - S17
  • [20] Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review
    Ugarte-Gil, Manuel Francisco
    Mendoza-Pinto, Claudia
    Reategui-Sokolova, Cristina
    Pons-Estel, Guillermo J.
    van Vollenhoven, Ronald F.
    Bertsias, George
    Alarcon, Graciela S.
    Pons-Estel, Bernardo A.
    LUPUS SCIENCE & MEDICINE, 2021, 8 (01):
12345